Stay updated on Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Sign up to get notified when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.

Latest updates to the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe study of Gilteritinib in combination with Ivosidenib or Enasidenib for Acute Myeloid Leukemia has been updated to reflect a new date of March 5, 2025, replacing the previous date of November 12, 2024.SummaryDifference2%
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check35 days agoNo Change Detected
- Check42 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check49 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check63 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.3%
- Check71 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant revision.SummaryDifference1.0%
Stay in the know with updates to Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Gilteritinib Combo with IDH Inhibitors in AML Clinical Trial page.